AI-assisted, human-published
12/03/2024 /Funding Events
Maze Therapeutics Secures $115M Series D Financing to Advance Precision Medicines for Renal and Metabolic Diseases
Maze Therapeutics raises $115 million to advance lead programs targeting kidney diseases and undergo Phase 2 trials for APOL1 kidney disease and Phase 1 trials for chronic kidney disease.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com